Federal Member for Capricornia Michelle Landry has welcomed more PBS listings which in this case will help those with Stage IV metastatic kidney cancer.
More than 800 Australians with stage IV advanced or metastatic kidney cancer will now have improved access to a heavily subsidised treatment through an expanded listing on the Pharmaceutical Benefits Scheme (PBS).
Michelle Landry said, “These listings of drugs on the PBS are so helpful because they give patients access to top line treatments that are often very expensive for the average person at an affordable price.”
From 1 July 2021, Cabometyx® (cabozantinib), will now be available as a first line treatment for Australians with stage IV clear cell variant renal cell carcinoma (RCC). It has been available as a second line treatment for patients with advanced RCC since 2018.
Taken once daily, the oral treatment blocks the action of proteins called receptor tyrosine kinases, slowing the rate at which the tumour grows and improving progression-free survival time compared with some other treatments.
“Kidney cancer is the seventh most diagnosed cancer in Australia, with an estimated 4,000 Australians diagnosed in 2020. RCC accounts for 90 per cent of all kidney cancers and is frequently diagnosed at an advanced stage.” Ms Landry said
Cabometyx® can cost around $120,000 a year without subsidy, but will now be available for $41.30 per script, or as little as $6.60 for patients with a concession card.
“Since 2013, the Australian Government has approved more than 2,600 new or amended listings on the PBS.
This represents an average of around 30 listings or amendments per month – or one each day – at an overall investment by the Government of $13.2 billion.
Providing the best quality care and support to Australians with deadly cancers is a high priority for our Government.” Ms Landry said
As part of the 2021-22 Budget we announced a number of measures to support our already strong national cancer screening programs and in April, there was a Ministerial Roundtable with Cancer Australia, the first step in the development of a visionary ten-year Australian Cancer Plan.
Ms Landry said, “These initiatives consolidate Australia as a world leader in the early detection and treatment of cancer.”